OBJECTIVES: Information on the epidemiology of end-stage liver disease (ESLD) in US correctional populations is limited. We examined the prevalence, mortality and clinical characteristics of ESLD in the nation's second largest state prison system. METHODS: We collected and analyzed medical and demographic data from 370,511 offenders incarcerated in Texas' prison system during a 3.5-year period. RESULTS: ESLD was diagnosed in 484 inmates (131/100,000); 213 (57/100,000) died of ESLD. Offenders who were Hispanic, 30-49 years of age, > or =50 years of age, HIV monoinfected, hepatitis C virus (HCV) monoinfected, or HIV/HCV coinfected had elevated ESLD prevalence and mortality rates. CONCLUSIONS: ESLD mortality in Texas' prison population is approximately 3 times higher than that of the general population, reflecting elevated rates of HCV and HIV/HCV coinfection among prisoners. Ultimately, the only viable treatment option for many prisoners with ESLD will be liver transplantation. The enormous costs of organ transplantation and immunosuppressive therapy are staggering and have the potential to decimate the healthcare budgets of most prison systems. Consequently, it is imperative that correctional healthcare programs expand HCV treatment and prevention strategies.
OBJECTIVES: Information on the epidemiology of end-stage liver disease (ESLD) in US correctional populations is limited. We examined the prevalence, mortality and clinical characteristics of ESLD in the nation's second largest state prison system. METHODS: We collected and analyzed medical and demographic data from 370,511 offenders incarcerated in Texas' prison system during a 3.5-year period. RESULTS: ESLD was diagnosed in 484 inmates (131/100,000); 213 (57/100,000) died of ESLD. Offenders who were Hispanic, 30-49 years of age, > or =50 years of age, HIV monoinfected, hepatitis C virus (HCV) monoinfected, or HIV/HCV coinfected had elevated ESLD prevalence and mortality rates. CONCLUSIONS: ESLD mortality in Texas' prison population is approximately 3 times higher than that of the general population, reflecting elevated rates of HCV and HIV/HCV coinfection among prisoners. Ultimately, the only viable treatment option for many prisoners with ESLD will be liver transplantation. The enormous costs of organ transplantation and immunosuppressive therapy are staggering and have the potential to decimate the healthcare budgets of most prison systems. Consequently, it is imperative that correctional healthcare programs expand HCV treatment and prevention strategies.
Authors: Sarah Larney; Madeline K Mahowald; Nicholas Scharff; Timothy P Flanigan; Curt G Beckwith; Nickolas D Zaller Journal: Am J Public Health Date: 2014-04-17 Impact factor: 9.308
Authors: Brie A Williams; Marc F Stern; Jeff Mellow; Meredith Safer; Robert B Greifinger Journal: Am J Public Health Date: 2012-06-14 Impact factor: 9.308
Authors: Amy J Harzke; Jacques G Baillargeon; Michael F Kelley; Pamela M Diamond; Karen J Goodman; David P Paar Journal: Ann Epidemiol Date: 2009-05-13 Impact factor: 3.797
Authors: Amy Jo Harzke; Jacques Baillargeon; David P Paar; John Pulvino; Owen J Murray Journal: Am J Gastroenterol Date: 2009-04-21 Impact factor: 10.864
Authors: Anne S Spaulding; Arthur Y Kim; Amy Jo Harzke; Jean C Sullivan; Benjamin P Linas; Arthur Brewer; Jeff Dickert; Barbara H McGovern; Lara B Strick; Robert Trestman; Warren J Ferguson Journal: Top Antivir Med Date: 2013 Feb-Mar
Authors: Jacques Baillargeon; Ned Snyder; Roger D Soloway; David Paar; Gwen Baillargeon; Anne C Spaulding; Brad H Pollock; Christine M Arcari; Brie A Williams; Ben G Raimer Journal: Public Health Rep Date: 2009 Jan-Feb Impact factor: 2.792
Authors: Micaela Brandolini; Stefano Novati; Annalisa De Silvestri; Carmine Tinelli; Savino Francesco Antonio Patruno; Roberto Ranieri; Elena Seminari Journal: BMC Public Health Date: 2013-10-20 Impact factor: 3.295